Preparation method of targeted antigen display MS2 phage VLPs nanoparticle vaccine

By targeting the binding of ligands to the MS2 capsid protein and using copper-free click chemistry, the problems of lack of targeting and biosafety in antigen display during MS2 phage VLPs vaccine preparation were solved, achieving efficient and safe antigen delivery and assembly.

CN121944100APending Publication Date: 2026-05-01ZHE JIANG XI DAO SHENG WU KE JI YOU XIAN GONG SI
0 Cites 0 Cited by

Patent Information

Application Number
CN202610081432.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-21
Publication Date
2026-05-01

AI Technical Summary

Technical Problem

Existing MS2 phage VLPs vaccine preparation technologies lack targeted antigen display, and traditional fusion or conjugation methods easily disrupt antigen conformation, resulting in low conjugation efficiency and the use of toxic catalysts, which affect immunization efficacy and production safety.

Method used

The design employs a targeted ligand binding to the MS2 capsid protein, achieving efficient binding of antigens to VLPs through an azide-alkynyl click chemistry reaction. This is combined with a molecular chaperone-assisted folding strategy to preserve the antigen conformation and avoid the use of copper ion catalysts.

Benefits of technology

This enables VLPs to accurately identify and bind to target cells, improve antigen delivery efficiency, maintain antigen immunogenicity, reduce non-specific binding and production costs, and ensure biosafety.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the technical field of biological vaccine preparation, and particularly relates to a preparation method of a targeted antigen displayed MS2 phage VLPs nanoparticle vaccine. The preparation method sequentially comprises the following steps: preparation and activation of a targeting ligand, fixed-point transformation and expression of MS2 bacteriophage capsid protein, preparation of targeting antigen-aptamer fusion protein, folding optimization and activity pre-verification of the antigen-aptamer fusion protein, self-assembly and antigen display of targeting MS2-VLPs, purification and characterization of targeting VLPs nanoparticles, and preparation of the vaccine preparation. On the basis, by introducing the targeting ligand aiming at the specific receptor on the surface of the antigen presenting cell, accurate recognition and combination of the VLPs vaccine on the target cell are realized, the problem that the antigen display lacks targeting is fundamentally solved, the antigen delivery efficiency is remarkably improved, the off-target effect is effectively reduced, and the antigen waste is avoided.
Need to check novelty before this filing date? Find Prior Art